Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

首圖 ST.GALLEN, Switzerland & STAMFORD, Conn. — (BUSINESS WIRE) — Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/h…


發佈留言